BEAM Earnings Date: Nov 3, 2026 (Estimated) — Beam Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is BEAM's next earnings date?
Beam Therapeutics Inc. (BEAM) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.15 on revenue of $8.8M.
How did BEAM do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Beam Therapeutics Inc. posted EPS of -$1.18 versus the -$1.11 estimate, a miss of 6.3%. Revenue was $490,000 against a $16.4M estimate. The stock's 1-day post-earnings move was +9.4%.
How much does BEAM stock move after earnings?
BEAM beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.2% (up or down) in the day after earnings.
About Beam Therapeutics Inc.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -1.11 | -1.18 | -6.31% | $490,000 | ❌ Miss | +9.42% | +5.29% | +12.00% |
| 2026-05-19 | Q1 2026 | -0.98 | -0.91 | +7.14% | $31.7M | ✅ Beat | -1.79% | +11.12% | +21.15% |
| 2026-02-24 | Q4 2025 | -1.12 | -0.10 | +91.07% | $114.1M | ✅ Beat | +13.98% | +1.27% | -15.46% |
| 2025-11-04 | Q3 2025 | -1.01 | -1.10 | -8.91% | $9.7M | ❌ Miss | -6.23% | -10.72% | +10.27% |
| 2025-08-05 | Q2 2025 | -1.07 | -1.00 | +6.54% | $8.5M | ✅ Beat | -2.20% | -10.22% | -1.88% |
| 2025-05-06 | Q1 2025 | -1.17 | -1.24 | -5.98% | $7.5M | ❌ Miss | -19.32% | -7.97% | -13.47% |
| 2025-02-25 | Q4 2024 | -1.28 | -1.09 | +14.84% | $30.1M | ✅ Beat | -3.09% | -18.48% | -24.59% |
| 2024-11-05 | Q3 2024 | -1.16 | -1.17 | -0.86% | $14.3M | ❌ Miss | -1.77% | +24.59% | +6.81% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY11 · $1.59B total
| Segment | Share | Revenue | YoY |
|---|---|---|---|
| Home And Security | 55.9% | $889.7M | — |
| Spirits | 44.1% | $702.7M | — |
By region
Q4 FY13 · $739.5M total
| Segment | Share | Revenue | YoY | Q2 FY12 | Q3 FY12 | Q4 FY12 | Q1 FY13 |
|---|---|---|---|---|---|---|---|
| North America | 55.9% | $413.6M | +5.8% | $370.1M | $380.1M | $391.1M | $364.0M |
| E M E A | 26.9% | $198.9M | — | — | — | — | — |
| Asia Pacific South America | 17.2% | $127.0M | -9.8% | $113.7M | $130.9M | $140.8M | $108.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.